Aberrant expression of COT is related to recurrence of papillary thyroid cancer

Medicine (United States)

Volumn 94, Issue 6, 2015, Pages

  Lee, Jandee ^a   Jeong, Seonhyang ^a   Park, Jae Hyun ^b   Lee, Cho Rok ^a   Ku, Cheol Ryong ^a   Kang, Sang Wook ^a   Jeong, Jong Ju ^a   Nam, Kee Hyun ^a   Shin, Dong Yeob ^a   Lee, Eun Jig ^a   Chung, Woong Youn ^a   Jo, Young Suk ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University Wonju   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

A RAF KINASE; B RAF KINASE; C RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; RADIOACTIVE IODINE; RAF PROTEIN; UNCLASSIFIED DRUG; DNA; MAP3K8 PROTEIN, HUMAN; MESSENGER RNA; ONCOPROTEIN;

ADULT; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; THYROID PAPILLARY CARCINOMA; TUMOR RECURRENCE; WESTERN BLOTTING; AGE; GENETICS; MORTALITY; PAPILLARY CARCINOMA; REAL TIME POLYMERASE CHAIN REACTION; THYROID TUMOR;

ADULT; AGE FACTORS; BLOTTING, WESTERN; CARCINOMA, PAPILLARY; DNA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAP KINASE KINASE KINASES; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS A-RAF; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYROID NEOPLASMS;

EID: 84928586113     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000548     Document Type: Article

References (52)

1. Mazzaferri EL, Sipos J. Should all patients with subcentimeter thyroid nodules undergo fine-needle aspiration biopsy and preoperative neck ultrasonography to define the extent of tumor invasion? Thyroid. 2008; 18: 597-602
2. Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007; 246: 375-431discussion 381-4
3. Sipos JA, Mazzaferri EL. The therapeutic management of differentiated thyroid cancer. Expert Opin Pharmacother. 2008; 9: 2627-2637
4. American Thyroid Association Guidelines Taskforce onThyroid N, Differentiated Thyroid C, Cooper DS, et al. . Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19: 1167-1214
5. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004; 5: 875-885
6. Bogoyevitch MA, Marshall CJ, Sugden PH. Hypertrophic agonists stimulate the activities of the protein kinases c-Raf and A-Raf in cultured ventricular myocytes. J Biol Chem. 1995; 270: 26303-26310
7. Corbit KC, Soh JW, Yoshida K, et al. Different protein kinase C is forms determine growth factor specificity in neuronal cells. Mol Cell Biol. 2000; 20: 5392-5403
8. Kao S, Jaiswal RK, Kolch W, et al. Identification of the mechanisms regulating the differential activation of the mapk cascade by epidermal growth factor and nerve growth factor in PC12 cells. J Biol Chem. 2001; 276: 18169-18177
9. Rebocho AP, Marais R. ARAF acts as a scaffold to stabilize BRAF: CRAF heterodimers. Oncogene. 2013; 32: 3207-3212
10. Mooz J, Oberoi-Khanuja TK, Harms GS, et al. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration. Sci Signal. 2014; 7: ra73
11. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010; 468: 968-972
12. Salmeron A, Ahmad TB, Carlile GW, et al. Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. EMBO J. 1996; 15: 817-826
13. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949-954
14. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A. 2008; 105: 3041-3046
15. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003; 88: 4393-4397
16. Puxeddu E, Moretti S, Elisei R, et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab. 2004; 89: 2414-2420
17. Yang H, Higgins B, Kolinsky K, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 2010; 70: 5518-5527
18. Xing M. BRAF V600E mutation and papillary thyroid cancer. JAMA. 2013; 310: 535
19. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-2516
20. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010; 468: 973-977
21. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010; 467: 596-599
22. Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 2011; 71: 7137-7140
23. Lito P, Rosen N, Solit DB. Tumor adaptation and resistance to RAF inhibitors. Nat Med. 2013; 19: 1401-1409
24. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wildtype RAF to activate the MAPK pathway and enhance growth. Nature. 2010; 464: 431-435
25. Montagut C, Sharma SV, Shioda T, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008; 68: 4853-4861
26. Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011; 480: 387-390
27. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014; 384: 319-328
28. Hayes DN, Lucas AS, Tanvetyanon T, et al. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012; 18: 2056-2065
29. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013; 3: 520-533
30. Dadu R, Devine C, Hernandez M, et al. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014; 99: 2086-2094
31. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102: 15545-15550
32. Cancer Genome Atlas Research, Network, Electronic address gue, Cancer Genome Atlas Research, N. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159: 676-690
33. Lin X, Cunningham ET Jr, Mu Y, et al. The proto-oncogene Cot kinase participates in CD3/CD28 induction of NF-kappaB acting through the NF-kappaB-inducing kinase and IkappaB kinases. Immunity. 1999; 10: 271-280
34. Bouwmeester T, Bauch A, Ruffner H, et al. A physical and functional map of the human TNF-Alpha/NF-kappa B signal transduction pathway. Nat Cell Biol. 2004; 6: 97-105
35. Vougioukalaki M, Kanellis DC, Gkouskou K, et al. Tpl2 kinase signal transduction in inflammation and cancer. Cancer Lett. 2011; 304: 80-89
36. King AJ, Patrick DR, Batorsky RS, et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 2006; 66: 11100-11105
37. Urner-Bloch U, Urner M, Stieger P, et al. Transient MEK inhibitorassociated retinopathy in metastatic melanoma. Ann Oncol. 2014; 25: 1437-1441
38. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAFmutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380: 358-365
39. Bollag G, Tsai J, Zhang J, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012; 11: 873-886
40. Shen CT, Qiu ZL, Luo QY. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-Analysis. Endocr Relat Cancer. 2014; 21: 253-261
41. Sriskantharajah S, Guckel E, Tsakiri N, et al. Regulation of experimental autoimmune encephalomyelitis by TPL-2 kinase. J Immunol. 2014; 192: 3518-3529
42. Chowdhury FZ, Estrada LD, Murray S, et al. Pharmacological inhibition of TPL2/MAP3K8 blocks human cytotoxic T lymphocyte effector functions. PLoS One. 2014; 9: e92187
43. Liu D, Hu S, Hou P, et al. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res. 2007; 13: 1341-1349
44. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009; 69: 4885-4893
45. Jeong JH, Bhatia A, Toth Z, et al. TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth. PLoS One. 2011; 6: e16205
46. Lee HW, Joo KM, Lim JE, et al. Tpl2 kinase impacts tumor growth and metastasis of clear cell renal cell carcinoma. Mol Cancer Res. 2013; 11: 1375-1386
47. Ben-Addi A, Mambole-Dema A, Brender C, et al. IkappaB kinaseinduced interaction of TPL-2 kinase with 14-3-3 is essential for Toll-like receptor activation of ERK-1 and-2 MAP kinases. Proc Natl Acad Sci U S A. 2014; 111: E2394-E2403
48. Ballak DB, van Essen P, van Diepen JA, et al. MAP3K8 (TPL2/COT) affects obesity-induced adipose tissue inflammation without systemic effects in humans and in mice. PLoS One. 2014; 9: e89615
49. Kim K, Kim G, Kim JY, et al. Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation. Carcinogenesis. 2014; 35: 1352-1361
50. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013; 13: 184-199
51. Krcova Z, Ehrmann J, Krejci V, et al. Tpl-2/Cot and COX-2 in breast cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008; 152: 21-25
52. Kim G, Khanal P, Kim JY, et al. COT phosphorylates prolylisomerase Pin1 to promote tumorigenesis in breast cancer. Mol Carcinog. 2013; DOI: 10.1002/mc.22101